IP Library Granted Patent US 7,910,623
Granted Patent B2
US 7,910,623 · App. 12/017,951 · Granted Mar 22, 2011

Synthesis of scabronines and analogues thereof

Assignee: Sloan-Kettering Institute for Cancer Research
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,910,623
App. No.
12/017,951
Granted
Mar 22, 2011
Kind
B2
Abstract

A novel synthesis of scabronines, which are related to a broader class of angularly fused tricyclic diterpenoids known as cyathanes, is provided. Scabronine G, its methyl ester derivative, and other analogs have been shown to have neurotrophic activity. Therefore, these compounds are particularly useful in treating neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, Huntington's diseases, etc. The invention provides for the synthesis of scabronines as well as analogs thereof. Pharmaceutical compositions and method of using the inventive compounds are also provided.

Claims (74)

1. A compound of the formula

wherein

each dashed line independently represents the absence of a bond or a carbon-carbon bond of a carbon-carbon double bond;

m is an integer between 0 and 3, inclusive;

n is an integer between 0 and 2, inclusive;

R is C(═O)R 1 or CN; wherein

R 1 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR A ; —OH; —C(═O)R A ; —CO 2 R A ; —CN; —SCN; —SR A ; —SH; —N(R A ) 2 ; —NHR A ; —NH 2 ; or —C(R A ) 3 ; wherein each occurrence of R A is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 2 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR B ; —OH; —C(═O)R B ; —CO 2 R B ; —CN; —SCN; —SR B ; —SH; —SOR B ; —SO 2 R B ; —NO 2 ; —N(R B ) 2 ; —NHR B ; —NH 2 ; —NHC(═O)R B ; —OC(═O)R B ; or —C(R B ) 3 ; wherein each occurrence of R B is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 3 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR C ; —OH; —C(═O)R C ; —CO 2 R C ; —CN; —SCN; —SR C ; —SH; —SOR C ; —SO 2 R C ; —NO 2 ; —N(R C ) 2 ; —NHR C ; —NH 2 ; —NHC(═O)R C ; —OC(═O)R C ; or —C(R C ) 3 ; wherein each occurrence of R C is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 4 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR D ; —OH; —C(═O)R D ; —CO 2 R D ; —CN; —SCN; —SR D ; —SH; —SOR D ; —SO 2 R D ; —NO 2 ; —N(R D ) 2 ; —NHR D ; —NH 2 ; —NHC(═O)R D ; —OC(═O)R D ; or —C(R D ) 3 ; wherein each occurrence of R D is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 5 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR E ; —OH; —C(═O)R E ; —CO 2 R E ; —CN; —SCN; —SR E ; —SH; —SOR E ; —SO 2 R E ; —NO 2 ; —N(R E ) 2 ; —NHR E ; —NH 2 ; —NHC(═O)R E ; —OC(═O)R E ; or —C(R E ) 3 ; wherein each occurrence of R E is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 6 is hydrogen; halogen; cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic; cyclic or acyclic, substituted or unsubstituted, branched or unbranched heteroaliphatic; substituted or unsubstituted, branched or unbranched acyl; substituted or unsubstituted, branched or unbranched aryl; substituted or unsubstituted, branched or unbranched heteroaryl; —OR F ; —OH; —C(═O)R F ; —CO 2 R F ; —CN; —SCN; —SR F ; —SH; —SOR F ; —SO 2 R F ; —NO 2 ; —N(R F ) 2 ; —NHR F ; —NH 2 ; —NHC(═O)R F ; —OC(═O)R F ; or —C(R F ) 3 ; wherein each occurrence of R F is independently a hydrogen, a protecting group, an aliphatic moiety, a heteroaliphatic moiety, an acyl moiety; an aryl moiety; a heteroaryl moiety; alkoxy; aryloxy; alkylthio; arylthio; amino, alkylamino, dialkylamino, heteroaryloxy; or heteroarylthio moiety;

R 5 and R 6 may be take together to form ═O, ═S, ═NR E , ═C(R E ) 2 , or a carbocyclic or heterocyclic moiety; or a therapeutically acceptable salt thereof;

wherein at least one of m and n is 1.

2. The compound of claim 1 of formula:

3. The compound of claim 1 of formula:

4. The compound of claim 1 of formula:

5. The compound of claim 1 of formula:

6. The compound of claim 1 of formula:

7. The compound of claim 1 of formula:

8. The compound of claim 1 of formula:

9. The compound of claim 1 of formula:

10. The compound of claim 1 of any one of the formulae:

11. The compound of claim 1 , having the formula:

12. The compound of claim 1 of any one of the formulae:

13. The compound of claim 1 of one of the formulae:

14. The compound of claim 1 , wherein m is 1.

15. The compound of claim 1 , wherein m is 2.

16. The compound of claim 1 , wherein m is 0.

17. The compound of claim 1 , wherein n is 1.

18. The compound of claim 1 , wherein n is 2.

19. The compound of claim 1 , wherein n is 0.

20. The compound of claim 1 , wherein m and n are both 1.

21. The compound of claim 1 , wherein R is C(═O)R 1 .

22. The compound of claim 21 , wherein R 1 is hydrogen.

23. The compound of claim 21 , wherein R 1 is —OR A .

24. The compound of claim 21 , wherein R 1 is —OH.

25. The compound of claim 21 , wherein R 1 is —OR A , wherein R A is C 1 -C 6 alkyl.

26. The compound of claim 21 , wherein R 1 is —OMe.

27. The compound of claim 21 , wherein R 1 is —N(R A ) 2 .

28. The compound of claim 1 , wherein R 2 is hydrogen.

29. The compound of claim 1 , wherein R 2 is C 1 -C 6 alkyl.

30. The compound of claim 1 , wherein R 2 is methyl.

31. The compound of claim 1 , wherein R 3 is hydrogen.

32. The compound of claim 1 , wherein R 3 is C 1 -C 6 alkyl.

33. The compound of claim 1 , wherein R 3 is —CHO.

34. The compound of claim 1 , wherein R 3 is acyl.

35. The compound of claim 1 , wherein R 3 is —CH 2 OR C .

36. The compound of claim 1 , wherein R 3 is —CH 2 OR C , wherein R C is hydrogen, C 1 -C 6 alkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

37. The compound of claim 1 , wherein R 3 is —CH 2 OH.

38. The compound of claim 1 , wherein R 4 is hydrogen.

39. The compound of claim 1 , wherein R 4 is C 1 -C 6 alkyl.

40. The compound of claim 1 , wherein R 4 is methyl.

41. The compound of claim 1 , wherein R 4 is ethyl.

42. The compound of claim 1 , wherein R 4 is propyl.

43. The compound of claim 1 , wherein R 4 is iso-propyl.

44. The compound of claim 1 , wherein R 4 is substituted or unsubstituted aryl.

45. The compound of claim 1 , wherein R 4 is substituted or unsubstituted heteroaryl.

46. The compound of claim 1 , wherein R 4 is acyl.

47. The compound of claim 1 , wherein R 5 is hydrogen.

48. The compound of claim 1 , wherein R 5 is —OR E .

49. The compound of claim 1 , wherein R 5 is —OH.

50. The compound of claim 1 , wherein R 6 is hydrogen.

51. The compound of claim 1 , wherein R 6 is —OR F .

52. The compound of claim 1 , wherein R 6 is —OH.

53. The compound of claim 1 , wherein R 5 is —OH; and R 6 is hydrogen.

54. The compound of claim 1 , wherein R 5 is hydrogen; and R 6 is —OH.

55. The compound of claim 1 , wherein R 5 and R 6 are taken together to be ═O.

56. The compound of claim 1 , wherein R 5 and R 6 are taken together to be ═S.

57. The compound of claim 1 , wherein R 5 and R 6 are taken together to be ═C(R E ) 2 .

58. The compound of claim 1 , wherein R 5 and R 6 are taken together to be ═NR E .

59. The compound of claim 1 , wherein R 5 and R 6 are taken together to be a carbocyclic or heterocyclic moiety optionally substituted.

60. The compound of claim 1 of one of the formulae:

61. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.

Assignments (3)
CONFIRMATORY LICENSE Recorded Apr 6, 2015
From: SLOAN-KETTERING INST CAN RESEARCH
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 035367/0794 →
RE-RECORD TO CORRECT THE EXECUTION DATE OF THE FIRST ASSIGNOR, PREVIOUSLY RECORDED ON REEL 021565 FRAME 0248. Recorded Oct 2, 2008
From: DANISHEFSKY, SAMUEL J.; WATERS, STEPHEN P.
To: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 021626/0672 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 22, 2008
From: DANISHEFSKY, SAMUEL J.; WATERS, STEPHEN P.
To: SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH
Reel/Frame 021565/0243 →
Continuity (1)
Related Publication 20110009485A9 · Jan 13, 2011